Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.53 |
| ▸ | CHRM4 known ✓ | P08173 | 2/20 | 0.53 |
| ▸ | CHRM5 known ✓ | P08912 | 2/20 | 0.53 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.53 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.53 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.44 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.44 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL19469275 | 1.00 | CHRM2 (0.53) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL29930859 | 0.99 | CHRM2 (0.51) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL19506334 | 0.99 | CHRM2 (0.51) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Bromide SCHEMBL5279859 | 0.86 | CA12 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Bromide SCHEMBL8848908 | 0.86 | CA12 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Bromide SCHEMBL28793443 | 0.84 | AOC3 (0.46) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL19506338 | 0.83 | CHRM2 (0.54) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL19519178 | 0.83 | CHRM2 (0.54) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL19469279 | 0.82 | CHRM2 (0.53) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL19469278 | 0.82 | CHRM2 (0.53) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10842846-B2 | Therapeutic inhibitor for EBV-associated tumor with tailor responsive optical imaging | HONG KONG BAPTIST UNIVERSITY (CN) | 2020-11-24 | — | — | US | claimed |
| EP-3448423-B1 | INHIBITOR FOR USE IN TREATING AND IMAGING EBV-ASSOCIATED TUMORS | UNIV HONG KONG BAPTIST UNIV (CN) | 2023-07-19 | — | — | EP | disclosed |
| US-10842846-B2 | Therapeutic inhibitor for EBV-associated tumor with tailor responsive optical imaging | HONG KONG BAPTIST UNIVERSITY (CN) | 2020-11-24 | — | — | US | disclosed |
| US-10137115-B2 | Therapeutic inhibitor for EBV-associated tumor with tailor responsive optical imaging | HONG KONG BAPTIST UNIVERSITY (HK) | 2018-11-27 | — | — | US | disclosed |
| US-20170304284-A1 | Therapeutic inhibitor for EBV-associated tumor with tailor responsive optical imaging | HONG KONG BAPTIST UNIVERSITY (HK) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10842846-B2 | Therapeutic inhibitor for EBV-associated tumor with tailor responsive optical imaging | EBNA1BP2, BID, TP53 | CHRM2 4834/4885CHRM4 4558/4885CHRM5 4803/4885 |
| US-10137115-B2 | Therapeutic inhibitor for EBV-associated tumor with tailor responsive optical imaging | RBBP4, TP53, EBNA1BP2 | CHRM2 4152/4885CHRM4 2397/4885CHRM5 4738/4885 |
| US-20170304284-A1 | Therapeutic inhibitor for EBV-associated tumor with tailor responsive optical imaging | RBBP4, TP53, EBNA1BP2 | CHRM2 4152/4885CHRM4 2397/4885CHRM5 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.